{"schema_version":"secwatch.filing_event.v1","accession":"0001641489-26-000011","form_type":"8-K","ticker":"VTVT","cik":"0001641489","company_name":"vTv Therapeutics Inc.","filed_at":"2026-03-10T23:59:59+00:00","discovered_at":"2026-05-14T18:02:35.725411+00:00","generated_at":"2026-05-15T16:41:40.105430+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"vTv Therapeutics reports 2025 net loss of $27M; cash $88.9M; Phase 3 enrollment Q3 2026","bullets":["Full-year 2025 net loss attributable to vTv of $27.0M ($3.20 basic EPS) vs $18.5M ($3.20 basic EPS) in 2024.","Cash and equivalents $88.9M at Dec 31, 2025, up from $36.7M; plus $20M non-dilutive from Newsoara in Feb 2026.","Expect to complete enrollment in Phase 3 CATT1 trial for cadisegliatin in T1D in Q3 2026.","R&D expenses rose to $17.9M in 2025 (2024: $11.5M) driven by higher cadisegliatin clinical spending.","Amended Newsoara license grants global rights to PDE4 inhibitor HPP737 for $20M upfront plus up to $115M milestones and royalties."],"urls":{"canonical":"https://secwatch.observer/filing/0001641489-26-000011","json":"https://secwatch.observer/filing/0001641489-26-000011.json","markdown":"https://secwatch.observer/filing/0001641489-26-000011.md","text":"https://secwatch.observer/filing/0001641489-26-000011.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1641489/000164148926000011/0001641489-26-000011-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1641489/000164148926000011/vtvt-20260310.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-15T16:41:40.105430+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}